Valeant Pharmaceuticals International, Inc. (VRX) belonging to the Healthcare sector has declined -0.29% and closed its last trading session at $17.24.
The company reported its EPS on 6/29/2010. The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 3.2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 3.2 and 3.18 respectively.
Valeant Pharmaceuticals International, Inc. on 6/29/2010 reported its EPS as $0.58 with the analysts projecting the EPS of the stock as $0.49. The company beat the analyst EPS Estimate with the difference of $0.09. This shows a surprise factor of 0.184%.
Analysts are also projecting an Average Revenue Estimate for Valeant Pharmaceuticals International, Inc. as $297080 in the Current Quarter. This estimate is provided by 5 analysts.
The High Revenue estimate is predicted as 333000, while the Low Revenue Estimate prediction stands at 270800. The company’s last year sales total was 220320.
In the past 5 years, the stock showed growth of 61.43% per annum. While for the next 5 years, the growth estimate is 15.24%.
Valeant Pharmaceuticals International, Inc. (VRX) has the market capitalization of $5.91 Billion. The company rocked its 52-Week High of $32.74 and touched its 52-Week Low of $8.31.
The stock has Return on Assets (ROA) of -3.1 percent. Return on Equity (ROE) stands at -34.1% and Return on Investment (ROI) of -1.6 percent.
The stock is currently showing YTD performance of 18.73 Percent. The company has Beta Value of -0.37 and ATR value of 0.75. The Weekly and Monthly Volatility stands at 2.99% and 4.95%.